About Orchard Therapeutics
Orchard Therapeutics is a company based in London (United Kingdom) founded in 2015 was acquired by Kyowa Kirin in October 2023.. Orchard Therapeutics has raised $440.31 million across 8 funding rounds from investors including TD Securities, Citadel and Baillie Gifford. The company has 117 employees as of December 31, 2020. Orchard Therapeutics offers products and services including HSC Gene Therapy Platform. Orchard Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Denali Therapeutics, among others.
- Headquarter London, United Kingdom
- Employees 117 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orchard Therapeutics (Europe) Limited
- Date of Incorporation 02 Sep, 2015
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
$22.66 M1253as on Dec 31, 2022
-
Net Profit
-
EBITDA
-
Total Equity Funding
$440.31 M (USD)
in 8 rounds
-
Latest Funding Round
-
Investors
TD Securities
& 30 more
-
Employee Count
117
as on Dec 31, 2020
-
Acquired by
Kyowa Kirin
(Oct 05, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orchard Therapeutics
Orchard Therapeutics offers a comprehensive portfolio of products and services, including HSC Gene Therapy Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for treating severe genetic diseases via stem cell gene therapy.
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Software Development Team
6 people
Product Management Team
4 people
Operations Team
4 people
Senior Team
4 people
Principal Team
4 people
Data Analysis and Operations Team
3 people
Sales and Marketing
3 people
Unlock access to complete
Funding Insights of Orchard Therapeutics
Orchard Therapeutics has successfully raised a total of $440.31M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Last Round
-
First Round
First Round
(03 May 2016)
- Investors Count 30
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2023 | Amount | Post-IPO - Orchard Therapeutics | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Orchard Therapeutics | Valuation |
investors |
|
| Oct, 2018 | Amount | Series C - Orchard Therapeutics | Valuation | Deerfield |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Orchard Therapeutics
Orchard Therapeutics has secured backing from 31 investors, including institutional and venture fund investors. Prominent investors backing the company include TD Securities, Citadel and Baillie Gifford. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Orchard Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Orchard Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orchard Therapeutics Comparisons
Competitors of Orchard Therapeutics
Orchard Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Denali Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orchard Therapeutics
Frequently Asked Questions about Orchard Therapeutics
When was Orchard Therapeutics founded?
Orchard Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Orchard Therapeutics located?
Orchard Therapeutics is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Who is the current CEO of Orchard Therapeutics?
Bobby Gaspar is the current CEO of Orchard Therapeutics.
Is Orchard Therapeutics a funded company?
Orchard Therapeutics is a funded company, having raised a total of $440.31M across 8 funding rounds to date. The company's 1st funding round was a Series C of $150M, raised on May 03, 2016.
How many employees does Orchard Therapeutics have?
As of Dec 31, 2020, the latest employee count at Orchard Therapeutics is 117.
What is the annual revenue of Orchard Therapeutics?
Annual revenue of Orchard Therapeutics is $22.66M as on Dec 31, 2022.
What does Orchard Therapeutics do?
Orchard Therapeutics was founded in 2015 and is based in London, United Kingdom. Operations are centered in the biotechnology sector, where a pipeline of hematopoietic stem cell gene therapies is advanced. Focus is placed on treating rare inherited disorders and neurometabolic conditions through ex-vivo approaches. Development efforts target transformative options for patients with orphan diseases, supported by clinical and research activities.
Who are the top competitors of Orchard Therapeutics?
Orchard Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Orchard Therapeutics offer?
Orchard Therapeutics offers HSC Gene Therapy Platform.
Who are Orchard Therapeutics's investors?
Orchard Therapeutics has 31 investors. Key investors include TD Securities, Citadel, Baillie Gifford, Temasek, and RTW Investments.